🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Spain / NCT07047131
Active, not recruiting Phase 3

Resorbable vs Non-resorbable Bone Substitute at Immediate Post-extractive Single Implants

NCT07047131 · tracked via the Priya Life Science Spain tracker
Sponsor
Marco Esposito
Phase
Phase 3
Started
2018-12-18
Last updated
2025-07-04

Condition(s) studied

Tooth ExtractionBone GraftAlveolar Bone LossDental Implant

Investigational drug(s) / intervention(s)

GTO® (fully resorbable bone substitute)Apatos® (partially resorbable bone substitute)

GTO® (fully resorbable bone substitute): Collagenated heterologous cortico-cancellous porcine bone mix + thermogelling copolymer with collagen (GTO®, OsteoBiol®, Tecnoss®)

Apatos® (partially resorbable bone substitute): Porcine cortical bone granules (Apatos Cortical®, OsteoBiol®, Tecnoss®) stabilized with TSV Gel®, a thermogelling copolymer with collagen.

Study summary

This study compares two bone graft materials used when placing a dental implant right after tooth removal. One graft fully dissolves (GTO®), the other only partly (Apatos®).

The goal is to see which one better preserves bone and improves appearance around the implant.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Any patient requiring at least one single immediate post-extractive implant. * At least 18 year old, able to understand and to sign an informed consent * There must be sufficient bone to allow the placement of at least a 3.5 mm diameter and 8.5 mm long implant. * After tooth extraction there must be a potential gap of at least 2 mm from the buccal inner bone plate and the implant surface. Exclusion Criteria: * General contraindications to implant surgery. * Immunosuppressed or immunocompromised patients. * Patients irradiated in the head and/or neck. * Uncontrolled diabetes. * Pregnancy or lactation. * Active periodontal disease * Poor oral hygiene and motivation. * Addiction to alcohol or drugs. * Psychiatric problems and/or unrealistic expectations * Patients with an acute infection (abscess) in the site intended for implant placement. * Patients unable to commit to a 5-year follow-up. * Patients treated or under treatment with intravenous amino-bisphosphonates. * patients referred only for implant placement if follow-ups cannot be done at treatment centre. * Patients participating in other studies, if the present protocol could not be fully adhered to. In case of doubts please contact the study coordinator.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
King Juan Carlos University Madrid Madrid

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07047131 on ClinicalTrials.gov ↗ ← All trials in Spain